title: Cyclophosphamide 4 g/m2 plus rhG-CSF for mobilization of circulating progenitor cells in malignant lymphomas.
abstract: We report the preliminary results of a study exploring the possibility of collecting circulating progenitor cells (PBSC) with a protocol based on the administration of single doses (4 g/m2) of cyclophosphamide and G-CSF (5 or 10-micrograms/kg) in 9 patients with non Hodgkin's lymphoma. The peak level of CD34+ cells occurred after a median of 10 days (range 8-11), generally coinciding with the median peak level of CFU-GM, with a mean 31.27 fold increase above basal levels. 3 (range 2-5) leukaphereses were required to harvest a median number of 25.1 x 10(4)/kg (8-105) CFU-GM and of 9.4 x 10(6)/kg (1.2-25) CD34+ cells. No difference was recorded between 5 and 10 micrograms/kg of G-CSF in terms of PBSC yield. In transplanted patients, a strong correlation was found between CD34+ cells infused/kg and platelet recovery (r = -0.8, p = 0.002). No toxicity was observed and apheretic procedures were regularly performed outpatiently. Our conclusion is that this protocol is particularly suitable for an outpatient treatment/collection program.
authors.affiliation: Hematology Department, V. Cervello Hospital, Palermo, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Indovina
authors.forename: G
authors.initials: G
authors.lastname: Liberti
authors.forename: I
authors.initials: I
authors.lastname: Majolino
authors.forename: F
authors.initials: F
authors.lastname: Buscemi
authors.forename: R
authors.initials: R
authors.lastname: Scimè
authors.forename: S
authors.initials: S
authors.lastname: Gentile
authors.forename: S
authors.initials: S
authors.lastname: Vasta
authors.forename: M
authors.initials: M
authors.lastname: Pampinella
authors.forename: V
authors.initials: V
authors.lastname: Cappuzzo
authors.forename: A
authors.initials: A
authors.lastname: Santoro
mesh_terms: D000328:Adult; D015703:Antigens, CD; D018952:Antigens, CD34; D001781:Blood Component Removal; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D014182:Transplantation, Autologous
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide